Answers are grounded in this paper and cite their sources.
This consensus document provides a practical stratification tool and treatment algorithm for the use of inclisiran to manage dyslipidemia in patients with chronic kidney disease.
In patients with chronic kidney disease (CKD), the burden of atherosclerotic cardiovascular disease (ASCVD) remains distinctively high. Management of dyslipidaemia in individuals with CKD is essential yet often deficient due to polypharmacy, poor adherence, and statin intolerance. Inclisiran, a small interfering RNA (siRNA) that targets hepatic proprotein convertase subtilisin/kexin type 9 (PCSK9) synthesis, offers an innovative, long-acting approach to lower LDL-cholesterol. This manuscript presents evidence-based recommendations based on available clinical trial evidence and collective specialist opinion. We propose a practical stratification tool (Inclisiran Suitability Stratification Tool for CKD) and treatment algorithm, comparing Inclisiran with other lipid-lowering agents to support individualized clinical decision-making.
No takes yet. Share an insight, caveat, or question.
Sharma et al. (2026) conducted a review in Chronic Kidney Disease. Inclisiran vs. Other lipid-lowering agents was evaluated. Inclisiran use in patients with chronic kidney disease is guided by a newly proposed stratification tool and treatment algorithm based on clinical trial evidence and specialist opinion.
Synapse has enriched 10 related papers. Consider them for comparative context: